Literature DB >> 11114699

Association between a variant in the 11 beta-hydroxysteroid dehydrogenase type 2 gene and primary hypertension.

O Melander1, M Orho-Melander, K Bengtsson, U Lindblad, L Råstam, L Groop, U L Hulthén.   

Abstract

The enzyme 11 beta-hydroxysteroid dehydrogenase type 2 (11BHSD2) converts cortisol to cortisone in the kidney, thereby protecting the mineralocorticoid receptor from the mineralocorticoid actions of cortisol. The syndrome of Apparent Mineralocorticoid Excess (AME), a rare monogenic form of early onset hypertension with autosomal recessive inheritance, is caused by homozygous or compound heterozygous loss of function mutations in the 11BHSD2 gene. Association has been reported between a microsatellite marker flanking the 11BHSD2 gene (D16S496) and primary hypertension. The aim of this study was to identify variants in the 11BHSD2 gene and to test if such variants or the D16S496 are associated with primary hypertension, in Swedes. To address this, the coding sequences of the 11BHSD2 gene was screened for mutations in 20 patients with primary hypertension with single strand conformation polymorphism and direct DNA sequencing techniques. A polymorphism was identified in exon 3; G534A (Glu178Glu). This polymorphism and the D16S496 microsatellite were tested for association with primary hypertension in a population consisting of 292 patients with primary hypertension and 263 normotensive control subjects. The frequency of G534G homozygotes was higher in patients with primary hypertension than in normotensive control subjects (92.8% vs 87.8%; P < 0.05). The allele frequencies of the D16S496 microsatellite did not differ between the two groups (chi(2) = 11.0, df = 10; P = 0.36). In conclusion, over-representation of individuals homozygous for the G534 allele in hypertensive patients compared with control subjects suggests that a mutation in linkage disequilibrium with the G534A polymorphism could increase susceptibility to primary hypertension. Journal of Human Hypertension (2000) 14, 819-823

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114699     DOI: 10.1038/sj.jhh.1001116

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

Review 1.  Glucocorticoid sensitivity in health and disease.

Authors:  Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders
Journal:  Nat Rev Endocrinol       Date:  2013-10-01       Impact factor: 43.330

2.  Aldosterone synthase C-344T, angiotensin II type 1 receptor A1166C and 11-β hydroxysteroid dehydrogenase G534A gene polymorphisms and essential hypertension in the population of Odisha, India.

Authors:  Manisha Patnaik; Pallabi Pati; Surendra N Swain; Manoj K Mohapatra; Bhagirathi Dwibedi; Shantanu K Kar; Manoranjan Ranjit
Journal:  J Genet       Date:  2014-12       Impact factor: 1.166

3.  11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.

Authors:  Carmen Campino; Cristian A Carvajal; Javiera Cornejo; Betty San Martín; Oliviero Olivieri; Giancesare Guidi; Giovanni Faccini; Francesco Pasini; Javiera Sateler; Rene Baudrand; Lorena Mosso; Gareth I Owen; Alexis M Kalergis; Oslando Padilla; Carlos E Fardella
Journal:  Endocrine       Date:  2009-10-31       Impact factor: 3.633

4.  Glucocorticoid response elements and 11 beta-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression.

Authors:  Yong Liu; Domagoj Mladinov; Jennifer L Pietrusz; Kristie Usa; Mingyu Liang
Journal:  Cardiovasc Res       Date:  2008-08-20       Impact factor: 10.787

Review 5.  Glucocorticoid therapy and ocular hypertension.

Authors:  Adnan Dibas; Thomas Yorio
Journal:  Eur J Pharmacol       Date:  2016-07-05       Impact factor: 4.432

6.  Metabolic profiling shows pre-existing mitochondrial dysfunction contributes to muscle loss in a model of ICU-acquired weakness.

Authors:  Paul R Kemp; Richard Paul; Aaron C Hinken; David Neil; Alan Russell; Mark J Griffiths
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-07-16       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.